How is pulmonary heart disease diagnosed?

Pulmonary heart disease is a disease in which broncho-pulmonary tissue, thoracic or pulmonary vascular lesions cause increased pulmonary vascular resistance, resulting in pulmonary hypertension and subsequent structural (or) and functional changes in the right ventricle. The onset of the disease is often seasonal, especially when the seasons change and the climate changes suddenly. Today, we will discuss how the diagnosis of pulmonary heart disease is confirmed. The common tests used to confirm the diagnosis of pulmonary heart disease include electrocardiogram, X-ray, cardiac ultrasound, and blood gas analysis. ECG changes are: P-wave voltage ≥0.22mV, RV1+SV5>1.05mV; X-ray manifestations are: right lower pulmonary artery dilatation, the transverse diameter is greater than or equal to 15 mm. The ratio of the transverse diameter to the tracheal transverse diameter was greater than or equal to 1.07. The transverse diameter of the left lower pulmonary artery was greater than or equal to 13 mm, and the protrusion of the pulmonary artery segment was greater than or equal to 3 mm. In the right anterior oblique position, the protrusion of the pulmonary artery cone is greater than or equal to 7 mm. The right ventricular wall thickness is greater than or equal to 5 mm, and the right pulmonary artery internal diameter is increased, or the main pulmonary artery internal diameter is greater than or equal to 20 mm. The compliance rate for the diagnosis of cardiac ultrasound is about 60% to 80%. Blood gas analysis in patients with pulmonary heart disease tends to show predominantly hypoxemia, and the partial pressure of carbon dioxide is not necessarily elevated. The diagnosis of pulmonary heart disease is generally not difficult; the difficulty is mainly in the treatment of pulmonary heart disease. Patients often have a poor prognosis and are prone to relapse, so they must pay attention to strengthening their resistance during the week, and if necessary, they can apply appropriate immunity-boosting drugs during the change of seasons to help delay the relapse and progression of the disease.